Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy
Dendritic cells (DCs) are the most potent antigen-presenting cells. They play a vital role in the initiation of immune response by presenting antigens to T cells and followed by induction of T-cell response. Reported research in animal studies indicated that vaccine immunity could be a promising alt...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2010/565643 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832556579259416576 |
---|---|
author | Yu-Zhe Chen Xing-Lei Yao Yasuhiko Tabata Shinsaku Nakagawa Jian-Qing Gao |
author_facet | Yu-Zhe Chen Xing-Lei Yao Yasuhiko Tabata Shinsaku Nakagawa Jian-Qing Gao |
author_sort | Yu-Zhe Chen |
collection | DOAJ |
description | Dendritic cells (DCs) are the most potent antigen-presenting cells. They play a vital role in the initiation of immune response by presenting antigens to T cells and followed by induction of T-cell response. Reported research in animal studies indicated that vaccine immunity could be a promising alternative therapy for cancer patients. However, broad clinical utility has not been achieved yet, owing to the low transfection efficiency of DCs. Therefore, it is essential to improve the transfection efficiency of DC-based vaccination in immunotherapy. In several studies, DCs were genetically engineered by tumor-associated antigens or by immune molecules such as costimulatory molecules, cytokines, and chemokines. Encouraging results have been achieved in cancer treatment using various animal models. This paper describes the recent progress in gene delivery systems including viral vectors and nonviral carriers for DC-based genetically engineered vaccines. The reverse and three-dimensional transfection systems developed in DCs are also discussed. |
format | Article |
id | doaj-art-ec818f1b949043c9b4880569420f97b4 |
institution | Kabale University |
issn | 1740-2522 1740-2530 |
language | English |
publishDate | 2010-01-01 |
publisher | Wiley |
record_format | Article |
series | Clinical and Developmental Immunology |
spelling | doaj-art-ec818f1b949043c9b4880569420f97b42025-02-03T05:44:56ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/565643565643Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer ImmunotherapyYu-Zhe Chen0Xing-Lei Yao1Yasuhiko Tabata2Shinsaku Nakagawa3Jian-Qing Gao4Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, ChinaInstitute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, ChinaDepartment of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawanara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, JapanInstitute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, ChinaDendritic cells (DCs) are the most potent antigen-presenting cells. They play a vital role in the initiation of immune response by presenting antigens to T cells and followed by induction of T-cell response. Reported research in animal studies indicated that vaccine immunity could be a promising alternative therapy for cancer patients. However, broad clinical utility has not been achieved yet, owing to the low transfection efficiency of DCs. Therefore, it is essential to improve the transfection efficiency of DC-based vaccination in immunotherapy. In several studies, DCs were genetically engineered by tumor-associated antigens or by immune molecules such as costimulatory molecules, cytokines, and chemokines. Encouraging results have been achieved in cancer treatment using various animal models. This paper describes the recent progress in gene delivery systems including viral vectors and nonviral carriers for DC-based genetically engineered vaccines. The reverse and three-dimensional transfection systems developed in DCs are also discussed.http://dx.doi.org/10.1155/2010/565643 |
spellingShingle | Yu-Zhe Chen Xing-Lei Yao Yasuhiko Tabata Shinsaku Nakagawa Jian-Qing Gao Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy Clinical and Developmental Immunology |
title | Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy |
title_full | Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy |
title_fullStr | Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy |
title_full_unstemmed | Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy |
title_short | Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy |
title_sort | gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy |
url | http://dx.doi.org/10.1155/2010/565643 |
work_keys_str_mv | AT yuzhechen genecarriersandtransfectionsystemsusedintherecombinationofdendriticcellsforeffectivecancerimmunotherapy AT xingleiyao genecarriersandtransfectionsystemsusedintherecombinationofdendriticcellsforeffectivecancerimmunotherapy AT yasuhikotabata genecarriersandtransfectionsystemsusedintherecombinationofdendriticcellsforeffectivecancerimmunotherapy AT shinsakunakagawa genecarriersandtransfectionsystemsusedintherecombinationofdendriticcellsforeffectivecancerimmunotherapy AT jianqinggao genecarriersandtransfectionsystemsusedintherecombinationofdendriticcellsforeffectivecancerimmunotherapy |